Stockscreener 앱 받기
55.12
0.95%
-0.53
시장 영업 전:
55.50
0.38
+0.69%
전일 마감가:
$55.65
열려 있는:
$55.65
하루 거래량:
1.45M
Relative Volume:
0.71
시가총액:
$10.65B
수익:
$3.29B
순이익/손실:
$268.74M
주가수익비율:
40.22
EPS:
1.3704
순현금흐름:
$759.12M
1주 성능:
-4.82%
1개월 성능:
+6.39%
6개월 성능:
+6.47%
1년 성능:
-1.99%
1일 변동 폭
$54.61
$55.83
1주일 범위
$54.61
$58.26
52주 변동 폭
$49.26
$66.28
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
55.12 | 10.76B | 3.29B | 268.74M | 759.12M | 1.3704 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-27 | 재개 | Morgan Stanley | Overweight |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-20 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-09-08 | 개시 | H.C. Wainwright | Neutral |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
Daily Brief United States: SpaceX, Crude Oil, DPC Holdings, CRB Commodity Index, Vistra , AnaptysBio Inc, Kardigan, Aes Corp, GE Vernova , Biomarin Pharmaceutical and more - Smartkarma
(BMRN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BioMarin shares drop 4% as Voxzogo trials are discontinued - MSN
Janus Henderson High-Yield Fund's BioMarin Pharmaceutical Inc(BMRN) Holding History - GuruFocus
BMRN News | BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) - ChartMill
Layoff Tracker: Genentech R&D cuts include longtime top exec - BioSpace
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Decent Value Play with Strong Fundamentals - ChartMill
BioMarin Pharmaceutical (BMRN) Gains 2.58% as Stock Approaches Key Resistance LevelDiagonal Spread Trade - newsline.com
BMRN Technical Analysis & Stock Price Forecast - Intellectia AI
BioMarin Pharmaceutical's Revenue Guidance Boost Reflects Pipeline Progress and Acquisition GrowthEarnings Cycle Report - newsline.com
Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Exploring A 54.74% Potential Upside - DirectorsTalk Interviews
BioMarin (BMRN) up 0.2% since last earnings report: Can it continue? - MSN
10 Most Undervalued Stocks to Buy and Hold for 2 Years - Insider Monkey
BMRN stock down on mixed results from rare disease therapy study - MSN
BioMarin's Voxzogo meets goal in late-stage study for hypochondroplasia - MSN
How BioMarin Pharma is Planning to Grow Their Revenue? - The American Reporter
BioMarin’s VOXZOGO Win In Hypochondroplasia Shapes Rare Disease Growth Story - Yahoo Finance
BioMarin Pharmaceutical Inc. 2026 8-K Filing Summary: Company Information, Stock Details, and SEC Compliance - Minichart
BioMarin (BMRN) director Athena Countouriotis receives 7,490-share RSU grant - Stock Titan
BioMarin (NASDAQ: BMRN) director receives 7,490-share RSU grant - Stock Titan
BioMarin (BMRN) director Maykin Ho receives 7,490 stock units - Stock Titan
Director at BioMarin (NASDAQ: BMRN) awarded 7,490 RSUs - Stock Titan
BioMarin (BMRN) director Mark Enyedy receives 7,490-share RSU grant - Stock Titan
BioMarin (BMRN) director Willard H. Dere receives 7,490-share RSU grant - Stock Titan
BioMarin (BMRN) director Ian T. Clark awarded 7,490 restricted stock units - Stock Titan
BioMarin (BMRN) director gets 7,490 RSUs, holds 21,045 shares - Stock Titan
BioMarin (BMRN) director receives 7,490 RSUs in stock grant - Stock Titan
BioMarin Shareholders Approve 2026 Governance and Equity Plan - TipRanks
Shareholders of BioMarin (NASDAQ: BMRN) back equity plan and board slate - Stock Titan
Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN
A Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Strength - Sahm
BioMarin gains on Voxzogo phase 3 results - MSN
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
BioMarin Pharmaceutical Hits Day High with 8.63% Surge in Stock Price - Markets Mojo
Responsive Playbooks and the BMRN Inflection - Stock Traders Daily
BioMarin Pharmaceutical Inc. (BMRN): Analyst Consensus Suggests a 53% Upside for a Biotech Innovator - DirectorsTalk Interviews
BMRN Q1 2026 Earnings: EPS Misses Estimates but Stock Surges 8.63%Earnings Power Value - newsline.com
BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development - Insider Monkey
5 Stocks That Could 10X by 2030 - Insider Monkey
Kim Warner Builds Pathways for Early-Career Professionals | BioMarin - BioMarin Pharmaceutical
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside - Investing.com
BioMarin Pharmaceutical (BMRN) Edges Higher as Biotech Sector Shows ResilienceRisk Reward Setups - newsline.com
Earnings call transcript: BioMarin Q1 2026 results beat forecasts, stock dips - Investing.com Nigeria
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
8 New 5-Star Stocks This Week - Morningstar
A Look At BioMarin Pharmaceutical (BMRN) Valuation After Positive Voxzogo Phase 3 Trial Results - Sahm
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Navigating a Potential 62.41% Upside Amidst Biotech Innovations - DirectorsTalk Interviews
CCORF Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Cuts Target Price to $111 - Moomoo
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today - Yahoo Finance
Understanding the Setup: (BMRN) and Scalable Risk - Stock Traders Daily
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):